DK614289A - CONJUGATES OF A MEMBRANE PROTEIN AND A PEPTIDE, THEIR PREPARATION AND USE - Google Patents

CONJUGATES OF A MEMBRANE PROTEIN AND A PEPTIDE, THEIR PREPARATION AND USE Download PDF

Info

Publication number
DK614289A
DK614289A DK614289A DK614289A DK614289A DK 614289 A DK614289 A DK 614289A DK 614289 A DK614289 A DK 614289A DK 614289 A DK614289 A DK 614289A DK 614289 A DK614289 A DK 614289A
Authority
DK
Denmark
Prior art keywords
conjugates
peptide
preparation
membrane protein
protein
Prior art date
Application number
DK614289A
Other languages
Danish (da)
Other versions
DK614289D0 (en
Inventor
Hermann Pelzer
Werner Stueber
Klaus-Dieter Hungerer
Original Assignee
Behringwerke Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke Ag filed Critical Behringwerke Ag
Publication of DK614289D0 publication Critical patent/DK614289D0/en
Publication of DK614289A publication Critical patent/DK614289A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/06—Peptides being immobilised on, or in, an organic carrier attached to the carrier via a bridging agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
DK614289A 1988-12-07 1989-12-06 CONJUGATES OF A MEMBRANE PROTEIN AND A PEPTIDE, THEIR PREPARATION AND USE DK614289A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3841091A DE3841091A1 (en) 1988-12-07 1988-12-07 SYNTHETIC ANTIGENS, METHOD FOR THEIR PRODUCTION AND THEIR USE

Publications (2)

Publication Number Publication Date
DK614289D0 DK614289D0 (en) 1989-12-06
DK614289A true DK614289A (en) 1990-06-08

Family

ID=6368560

Family Applications (1)

Application Number Title Priority Date Filing Date
DK614289A DK614289A (en) 1988-12-07 1989-12-06 CONJUGATES OF A MEMBRANE PROTEIN AND A PEPTIDE, THEIR PREPARATION AND USE

Country Status (8)

Country Link
EP (1) EP0372501A3 (en)
JP (1) JPH02223599A (en)
KR (1) KR900009095A (en)
AU (1) AU4589289A (en)
CA (1) CA2004810A1 (en)
DE (1) DE3841091A1 (en)
DK (1) DK614289A (en)
PT (1) PT92499A (en)

Families Citing this family (172)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7118757B1 (en) 1988-12-19 2006-10-10 Wyeth Holdings Corporation Meningococcal class 1 outer-membrane protein vaccine
EP0467714A1 (en) * 1990-07-19 1992-01-22 Merck & Co. Inc. The class II protein of the outer membrane of neisseria meningitidis
EP0519554A1 (en) * 1991-06-19 1992-12-23 Merck & Co. Inc. Conjugates of the class II protein of the outer membrane of neisseria meningitidis and of HIV-1 related peptides
DE69737413T2 (en) 1996-01-04 2007-10-31 Novartis Vaccines and Diagnostics, Inc., Emeryville BACTERIOFERRITINE FROM HELICOBACTER PYLORI
EP2284183A1 (en) 2000-10-27 2011-02-16 Novartis Vaccines and Diagnostics S.r.l. Nucleic acids and proteins from streptococcus groups A and B
US7082569B2 (en) 2001-01-17 2006-07-25 Outlooksoft Corporation Systems and methods providing dynamic spreadsheet functionality
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
EP2335724A1 (en) 2001-12-12 2011-06-22 Novartis Vaccines and Diagnostics S.r.l. Immunisation against chlamydia trachomatis
ES2607431T3 (en) 2002-02-20 2017-03-31 Glaxosmithkline Biologicals Sa Microparticles with molecules containing adsorbed polypeptides
MXPA04011249A (en) 2002-05-14 2005-06-06 Chiron Srl Mucosal vaccines with chitosan adjuvant and meningococcal antigens.
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
JP4697706B2 (en) 2002-10-11 2011-06-08 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル Polypeptide-vaccine for broad protection against highly virulent meningococcal strains
EP1562982B1 (en) 2002-11-15 2010-05-05 Novartis Vaccines and Diagnostics S.r.l. Unexpected surface proteins in neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
WO2004060396A2 (en) 2002-12-27 2004-07-22 Chiron Corporation Immunogenic compositions containing phospholpid
CA3042073C (en) 2003-01-30 2022-09-13 Novartis Vaccines And Diagnostics S.R.L. Injectable vaccines against multiple meningococcal serogroups
US7893096B2 (en) 2003-03-28 2011-02-22 Novartis Vaccines And Diagnostics, Inc. Use of small molecule compounds for immunopotentiation
CA2528007C (en) 2003-06-02 2012-03-27 Chiron Corporation Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen
JP4738339B2 (en) 2003-10-02 2011-08-03 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル Liquid vaccine for multiple meningococcal serogroups
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
GB0406013D0 (en) 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
GB0408978D0 (en) 2004-04-22 2004-05-26 Chiron Srl Meningococcal fermentation for preparing conjugate vaccines
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
GB0411387D0 (en) 2004-05-21 2004-06-23 Chiron Srl Analysis of saccharide length
GB0413868D0 (en) 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
CA2571710A1 (en) 2004-06-24 2006-11-02 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
WO2006002422A2 (en) 2004-06-24 2006-01-05 Novartis Vaccines And Diagnostics Inc. Compounds for immunopotentiation
US20090317420A1 (en) 2004-07-29 2009-12-24 Chiron Corporation Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0502096D0 (en) 2005-02-01 2005-03-09 Chiron Srl Purification of streptococcal capsular polysaccharide
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
NZ561042A (en) 2005-02-18 2011-03-31 Novartis Vaccines & Diagnostic Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli - SEQ ID: 7052
NZ580974A (en) 2005-02-18 2011-05-27 Novartis Vaccines & Diagnostic Immunogens from uropathogenic escherichia coli
SG175456A1 (en) 2005-04-18 2011-11-28 Novartis Vaccines & Diagnostic Expressing hepatitis b virus surface antigen for vaccine preparation
CN103083657B (en) 2005-06-27 2016-06-08 葛兰素史密丝克莱恩生物有限公司 Immunogenic composition
WO2007026249A2 (en) 2005-09-01 2007-03-08 Novartis Vaccines And Diagnostics Gmbh & Co Kg Multiple vaccination including serogroup c meningococcus
GB0522303D0 (en) 2005-11-01 2005-12-07 Chiron Srl Culture method
GB0522765D0 (en) 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
CA2630220C (en) 2005-11-22 2020-10-13 Doris Coit Norovirus and sapovirus antigens
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
KR101515078B1 (en) 2005-12-22 2015-04-24 글락소스미스클라인 바이오로지칼즈 에스.에이. Vaccines
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
TR201807355T4 (en) 2006-03-22 2018-06-21 Glaxosmithkline Biologicals Sa Immunization regimens with meningococcal conjugates.
GB0605757D0 (en) 2006-03-22 2006-05-03 Chiron Srl Separation of conjugated and unconjugated components
CA2646539A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
EP2035035A2 (en) 2006-06-09 2009-03-18 Novartis AG Immunogenic compositions for streptococcus agalactiae
GB0612854D0 (en) 2006-06-28 2006-08-09 Novartis Ag Saccharide analysis
EP2586790A3 (en) 2006-08-16 2013-08-14 Novartis AG Immunogens from uropathogenic Escherichia coli
CA2662064A1 (en) 2006-09-07 2008-03-13 Glaxosmithkline Biologicals S.A. Method of producing a combination polivirus vaccine
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
BRPI0810778A2 (en) 2007-05-02 2011-09-13 Glaxosmithkline Biolog Sa kit, combined vaccine, and methods of decreasing crm neighborhood interference over a sensitive antigen in a primary immunization schedule of a vaccine, and decreasing neighborhood interference over a sensitive antigen, and use of saccharide conjugates
ES2552366T3 (en) 2007-06-26 2015-11-27 Glaxosmithkline Biologicals S.A. Vaccine comprising capsular polysaccharide conjugates of Streptococcus pneumoniae
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
MX2010002773A (en) 2007-09-12 2010-03-31 Novartis Ag Gas57 mutant antigens and gas57 antibodies.
EP2200642B1 (en) 2007-10-19 2012-04-18 Novartis AG Meningococcal vaccine formulations
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
CN104292312A (en) 2007-12-21 2015-01-21 诺华股份有限公司 Mutant forms of streptolysin o
US9579372B2 (en) 2008-02-21 2017-02-28 Glaxosmithkline Biologicals Sa Meningococcal fHBP polypeptides
CN102264444B (en) 2008-10-27 2015-08-05 诺华股份有限公司 Purification process
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
MX2011006648A (en) 2008-12-17 2011-10-14 Novartis Ag Meningococcal vaccines including hemoglobin receptor.
EP2384120B1 (en) 2009-01-05 2019-12-11 Epitogenesis Inc. Adjuvant compositions and methods of use
NZ594029A (en) 2009-01-12 2014-01-31 Novartis Ag Cna_b domain antigens in vaccines against gram positive bacteria
DK2510947T3 (en) 2009-04-14 2016-03-21 Glaxosmithkline Biolog Sa Compositions for Immunization against Staphylococcus aureus.
WO2010125480A1 (en) 2009-04-30 2010-11-04 Coley Pharmaceutical Group, Inc. Pneumococcal vaccine and uses thereof
WO2010132833A1 (en) 2009-05-14 2010-11-18 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
US20110076300A1 (en) 2009-08-27 2011-03-31 Mariagrazia Pizza Hybrid Polypeptides Including Meningococcal fHBP Sequences
CA2771770A1 (en) 2009-09-03 2011-03-10 Pfizer Vaccines Llc Pcsk9 vaccine
WO2011030218A1 (en) 2009-09-10 2011-03-17 Novartis Ag Combination vaccines against respiratory tract diseases
EP2483390A2 (en) 2009-09-30 2012-08-08 Novartis AG Expression of meningococcal fhbp polypeptides
AU2010352695B2 (en) 2009-09-30 2014-08-21 Glaxosmithkline Biologicals S.A. Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides
CA2779816A1 (en) 2009-10-27 2011-05-05 Novartis Ag Modified meningococcal fhbp polypeptides
US9060965B2 (en) 2009-10-30 2015-06-23 Glaxosmithkline Biologicals Sa Purification of Staphylococcus aureus type 5 capsular saccharides
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
JP2013532008A (en) 2010-05-28 2013-08-15 テトリス オンライン インコーポレイテッド Interactive hybrid asynchronous computer game infrastructure
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
EP2655389A2 (en) 2010-12-24 2013-10-30 Novartis AG Compounds
ES2612511T3 (en) 2011-01-27 2017-05-17 Glaxosmithkline Biologicals Sa Adjuvant nanoemulsions with crystallization inhibitors
WO2012131504A1 (en) 2011-03-02 2012-10-04 Pfizer Inc. Pcsk9 vaccine
GB201103836D0 (en) 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
US10357568B2 (en) 2011-03-24 2019-07-23 Glaxosmithkline Biologicals S.A. Adjuvant nanoemulsions with phospholipids
EP2511295A1 (en) 2011-04-15 2012-10-17 Institut National De La Sante Et De La Recherche Medicale Compositions for preventing and/or treating an infection by an HIV-1 virus
CA2839507A1 (en) 2011-06-24 2012-12-27 Epitogenesis Inc. Pharmaceutical compositions, comprising a combination of select carriers, vitamins, tannins and flavonoids as antigen-specific immuno-modulators
US9149541B2 (en) 2011-07-08 2015-10-06 Novartis Ag Tyrosine ligation process
GB201114923D0 (en) 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
US9358284B2 (en) 2011-09-14 2016-06-07 Glaxosmithkline Biologicals Sa Methods for making saccharide-protein glycoconjugates
CA2854934A1 (en) 2011-11-07 2013-05-16 Novartis Ag Carrier molecule comprising a spr0096 and a spr2021 antigen
DE102011118371B4 (en) 2011-11-11 2014-02-13 Novartis Ag Composition suitable for human vaccination, comprising a diphtheria toxoid, and process for its preparation
DE102011122891B4 (en) 2011-11-11 2014-12-24 Novartis Ag Fermentation medium, which is free of animal components, for the preparation of diphtheria toxoids for use in the vaccination of humans
EP2592137A1 (en) 2011-11-11 2013-05-15 Novartis AG Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use
GB2495341B (en) 2011-11-11 2013-09-18 Novartis Ag Fermentation methods and their products
WO2013084071A2 (en) 2011-12-08 2013-06-13 Novartis Ag Clostridium difficile toxin-based vaccine
GB201121301D0 (en) 2011-12-12 2012-01-25 Novartis Ag Method
WO2013124473A1 (en) 2012-02-24 2013-08-29 Novartis Ag Pilus proteins and compositions
WO2013131983A1 (en) 2012-03-07 2013-09-12 Novartis Ag Adjuvanted formulations of streptococcus pneumoniae antigens
SA115360586B1 (en) 2012-03-09 2017-04-12 فايزر انك Neisseria meningitidis compositions and methods thereof
EP3804749A3 (en) 2012-04-26 2021-07-28 GlaxoSmithKline Biologicals S.A. Antigens and antigen combinations
US10279026B2 (en) 2012-04-26 2019-05-07 Glaxosmithkline Biologicals Sa Antigens and antigen combinations
ES2820898T3 (en) 2012-05-22 2021-04-22 Glaxosmithkline Biologicals Sa Meningococcal serogroup X conjugate
WO2014053612A1 (en) 2012-10-03 2014-04-10 Novartis Ag Immunogenic composition
JP6440619B2 (en) 2012-10-12 2018-12-19 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Uncrosslinked acellular pertussis antigen for combination vaccines
ES2826555T3 (en) 2012-11-30 2021-05-18 Glaxosmithkline Biologicals Sa Pseudomonas antigens and antigen combination
JP6411378B2 (en) 2013-02-01 2018-10-24 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Intradermal delivery of an immunological composition comprising a TOLL-like receptor agonist
KR20210002757A (en) 2013-09-08 2021-01-08 화이자 인코포레이티드 Neisseria meningitidis compositions and methods thereof
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
KR102049826B1 (en) 2014-01-21 2019-12-03 화이자 인코포레이티드 Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
NZ759686A (en) 2014-01-21 2023-07-28 Pfizer Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
BR122023022294A2 (en) 2014-01-21 2023-12-12 Pfizer Inc. USE OF AN IMMUNOGENIC COMPOSITION COMPRISING AN IMMUNOGENIC CONJUGATE COMPRISING A CAPSULAR POLYSACCHARIDE ISOLATED FROM STREPTOCOCCUS PNEUMONIAE OF SEROTYPE 15B
EP3443983B1 (en) 2014-02-14 2022-07-20 Pfizer Inc. Immunogenic glycoprotein conjugates
WO2015128480A1 (en) 2014-02-28 2015-09-03 Novartis Ag Modified meningococcal fhbp polypeptides
EP3034516A1 (en) 2014-12-19 2016-06-22 Novartis AG Purification of streptococcal capsular polysaccharide
KR102149760B1 (en) 2015-01-15 2020-08-31 화이자 인코포레이티드 Immunogenic composition for use in pneumococcal vaccine
WO2016184962A1 (en) 2015-05-19 2016-11-24 Innavirvax Treatment of hiv-infected individuals
WO2016184963A1 (en) 2015-05-19 2016-11-24 Innavirvax Treatment of hiv-infected individuals
EP3109255A1 (en) 2015-06-26 2016-12-28 Institut National De La Recherche Agronomique Immunogenic composition
TWI756893B (en) 2015-07-21 2022-03-01 美商輝瑞股份有限公司 Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
US10786561B2 (en) 2015-11-20 2020-09-29 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
RU2747296C2 (en) 2015-12-04 2021-05-04 Дана-Фарбер Кэнсер Инститьют, Инк. Vaccination using the alpha 3 domain of mica/b for cancer treatment
WO2017175082A1 (en) 2016-04-05 2017-10-12 Gsk Vaccines S.R.L. Immunogenic compositions
US20190282684A1 (en) 2016-09-02 2019-09-19 Glaxosmithkline Biologicals, S.A. Vaccines for neisseria gonorrhoeae
CN117801069A (en) 2016-10-07 2024-04-02 恩特罗姆公司 Immunogenic compounds for cancer therapy
US11478537B2 (en) 2016-10-07 2022-10-25 Enterome S.A. Immunogenic compounds for cancer therapy
EP3551668A1 (en) 2016-12-06 2019-10-16 GlaxoSmithKline Biologicals S.A. Purification process for capsular polysaccharide
EP3570879B1 (en) 2017-01-20 2022-03-30 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
IL303108B1 (en) 2017-01-31 2024-03-01 Pfizer Neisseria meningitidis compositions and methods thereof
WO2019197567A2 (en) 2018-04-11 2019-10-17 Enterome S.A. Antigenic peptides for prevention and treatment of cancer
US20210106652A1 (en) 2018-04-11 2021-04-15 Enterome S.A. Immunogenic Compounds For Treatment Of Fibrosis, Autoimmune Diseases And Inflammation
CN112673054A (en) 2018-07-19 2021-04-16 葛兰素史密丝克莱恩生物有限公司 Process for preparing dried polysaccharides
EP3607967A1 (en) 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
US20220016229A1 (en) 2018-12-12 2022-01-20 Pfizer Inc. Immunogenic Multiple Hetero-Antigen Polysaccharide-Protein Conjugates and uses thereof
US20220118072A1 (en) 2019-02-11 2022-04-21 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
JP7239509B6 (en) 2019-02-22 2023-03-28 ファイザー・インク Method for purifying bacterial polysaccharides
CA3136278A1 (en) 2019-04-10 2020-10-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
EP3965826A1 (en) 2019-05-10 2022-03-16 GlaxoSmithKline Biologicals S.A. Conjugate production
BR112022001654A2 (en) 2019-07-31 2022-07-12 Sanofi Pasteur Inc CONJUGATED COMPOSITIONS OF MULTIVALENT PNEUMOCOCCUS POLYSACCHARIDE PROTEINS AND METHODS OF USE THEREOF
BR112022004921A2 (en) 2019-09-27 2022-07-19 Pfizer COMPOSITIONS FOR NEISSERIA MENINGITIDIS AND METHODS THEREOF
MX2022004598A (en) 2019-10-16 2022-09-23 Enterome S A Immunogenic compounds for treatment of adrenal cancer.
WO2021084429A1 (en) 2019-11-01 2021-05-06 Pfizer Inc. Escherichia coli compositions and methods thereof
DK4021487T3 (en) 2019-11-15 2024-02-12 Enterome S A ANTIGENIC PEPTIDES FOR THE PREVENTION AND TREATMENT OF B-CELL MALIGNANCY
JP2023503086A (en) 2019-11-22 2023-01-26 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Dosage and Dosage of Bacterial Saccharide Glycoconjugate Vaccines
CN115362177A (en) 2020-02-21 2022-11-18 辉瑞公司 Purification of saccharides
JP2023514697A (en) 2020-02-23 2023-04-07 ファイザー・インク E. coli composition and method
EP4165064A2 (en) 2020-06-12 2023-04-19 GlaxoSmithKline Biologicals S.A. Dock tag system
GB202013262D0 (en) 2020-08-25 2020-10-07 Glaxosmithkline Biologicals Sa Vaccine Composition
JP2023546446A (en) 2020-10-22 2023-11-02 ファイザー・インク How to purify bacterial polysaccharides
KR20230096033A (en) 2020-10-27 2023-06-29 화이자 인코포레이티드 Escherichia coli composition and method thereof
CN116744965A (en) 2020-11-04 2023-09-12 辉瑞大药厂 Immunogenic compositions for pneumococcal vaccines
US20220202923A1 (en) 2020-12-23 2022-06-30 Pfizer Inc. E. coli fimh mutants and uses thereof
EP4070814A1 (en) 2021-04-07 2022-10-12 Lama France Sars-cov-2 polypeptides and uses thereof
EP4333879A1 (en) 2021-05-03 2024-03-13 Pfizer Inc. Vaccination against bacterial and betacoronavirus infections
WO2022234416A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
TW202306969A (en) 2021-05-28 2023-02-16 美商輝瑞大藥廠 Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
AU2022281543A1 (en) 2021-05-28 2023-11-23 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2023135515A1 (en) 2022-01-13 2023-07-20 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
WO2023187127A1 (en) 2022-03-31 2023-10-05 Enterome S.A. Antigenic peptides for prevention and treatment of cancer
WO2023218322A1 (en) 2022-05-11 2023-11-16 Pfizer Inc. Process for producing of vaccine formulations with preservatives
GB202208093D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
GB202208089D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0289110A3 (en) * 1987-02-02 1990-01-24 Swiss Serum and Vaccine Institute Berne Conjugate malaria vaccine

Also Published As

Publication number Publication date
EP0372501A2 (en) 1990-06-13
CA2004810A1 (en) 1990-06-07
DE3841091A1 (en) 1990-06-13
EP0372501A3 (en) 1990-10-10
AU4589289A (en) 1990-06-14
JPH02223599A (en) 1990-09-05
KR900009095A (en) 1990-07-02
DK614289D0 (en) 1989-12-06
PT92499A (en) 1990-06-29

Similar Documents

Publication Publication Date Title
DK614289D0 (en) CONJUGATES OF A MEMBRANE PROTEIN AND A PEPTIDE, THEIR PREPARATION AND USE
NO893678D0 (en) CYCLOSPOR-CONTAINING PREPARATIONS AND PROCEDURES FOR THEIR PREPARATION.
DK374389A (en) ARYLBENZENOXAZOLIDINONES, THEIR PREPARATION AND USE
DK8189A (en) ANTIGEN-ANTIBODY CONJUGATES, THEIR PREPARATION AND USE
DK446389A (en) CYCLOHEXAPEPTIDE, PREPARATION CONTAINING SUCH A CONNECTION AND USE OF CYCLOHEXAPEPTIDE
DK209188A (en) BIFUNCTIONAL PROTEINS, THEIR PREPARATION AND USE AS A MEDICINE
DK388989D0 (en) ACYLCYANOGUANIDINES, THEIR PREPARATION AND USE
DK435289D0 (en) PIPERAZINDIONS, THEIR PREPARATION AND USE
DK400287A (en) RECOMBINANT HTLV-III PROTEINS AND USES THEREOF
DK695388D0 (en) DERIVATIVES OF CYCLIC AMINO ACIDS, THEIR PREPARATION AND USE
DK698188D0 (en) PEPTIDES, THEIR PREPARATION AND USE
DK225089D0 (en) 2-ADAMANTYL-4-ISOTHIAZOLIN-3-ONES, THEIR PREPARATION AND USE
DK51789A (en) AMINO ACID AMIDES, THEIR PREPARATION AND USE
DK703588D0 (en) PAI-1 BLOCKING PEPTIDES, THEIR PREPARATION AND USE
DK185489D0 (en) IMIDAZOLYLMETHYL-CYCLOALKANOEBAA INDOLONES, THEIR PREPARATION AND USE
DK592389D0 (en) PENEMDERIVATIVES, THEIR PREPARATION AND USE
DK421589D0 (en) FLANKING PEPTIDES AND THEIR PREPARATION AND USE
DK224187A (en) CYCLIC PEPTIDES, THEIR PREPARATION AND USE
DK630289A (en) COMPETITIVE PEPTID ANTAGONISTS FOR GONADOLIBERIN, THEIR PREPARATION AND USE
DK661489D0 (en) EXPRESSION PLASMIDS FOR EXPRESSION OF PROTEINS IN E. COLI AND THEIR USE
DK578689D0 (en) PURE-INHIBITIVE DIPEPTIDES, THEIR PREPARATION AND USE
DK132787D0 (en) PROTEIN CONJUGATES OF BIS-INDOL ALKALOIDS, BIS-INDOL ALKALOIDS, THEIR PREPARATION AND USE
NO924738D0 (en) RECOMBINANT PROTEINS AND THEIR PROCEDURES
NO900703L (en) IMPROVED HERBICIDE PREPARATIONS AND THEIR USE.
DK163589A (en) SAKYOMYCIN E AND DERIVATIVES THEREOF, THEIR PREPARATION AND USE

Legal Events

Date Code Title Description
ATS Application withdrawn